避妊薬市場：薬剤クラス別、性別、流通別、地域別、機会、予測、2017年～2031年

世界の避妊薬の市場規模は、予測期間の2024年～2031年に7.77%のCAGRで拡大し、2023年の191億9,000万米ドルから2031年には349億2,000万米ドルに成長すると予測されています。避妊薬の市場需要は、家族計画に対する意識の高まり、女性の健康製品に対する需要の高まり、市場の成長に寄与する様々な技術の進歩により、予測期間中に盛んになると予測されます。

避妊薬は、望まない妊娠を防ぎ、避妊率を高め、性感染症（STD）のリスクを軽減する方法です。主に、経口避妊薬、ピルなどの注射薬、長期的にホルモンを放出するインプラントなどのホルモン避妊薬が含まれます。これらの薬は、ホルモンを調節して排卵を抑えたり、子宮内膜を変化させたり、子宮頸管粘液を薄くしたりして、受精の可能性を減らす働きをします。避妊薬には、妊娠を防ぐという主な働きに加え、月経周期を整えたり、月経痛を軽減したり、特定の生殖に関する健康問題のリスクを軽減したりするなどの特典もあります。効果的な家族計画オプションに対する需要の高まりは、製剤やデリバリー方法の進歩と相まって避妊薬市場の技術革新を促し、リプロダクティブヘルスケアの重要な側面となっています。

当レポートでは、世界の避妊薬市場について調査し、市場の概要とともに、薬剤クラス別、性別、流通別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の避妊薬市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 薬剤クラス別
  • 性別
  • 流通別
  • 地域別

第5章 北米の避妊薬市場の見通し、2017年～2031年

第6章 欧州の避妊薬市場の見通し、2017年～2031年

第7章 アジア太平洋の避妊薬市場の見通し、2017年～2031年

第8章 南米の避妊薬市場の見通し、2017年～2031年

第9章 中東・アフリカの避妊薬市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場参入企業トップ10の情勢
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Piramal Enterprises Ltd
  • AbbVie Inc.
  • Veru Inc.
  • Maxwellia Ltd.
  • Perrigo Company plc.
  • Viatris Inc.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 3. Global Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 4. Global Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 5. Global Contraceptive Drugs Market Share (%), By Region, 2017-2031F
• Figure 6. North America Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 8. North America Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 9. North America Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 10. North America Contraceptive Drugs Market Share (%), By Country, 2017-2031F
• Figure 11. United States Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 13. United States Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 14. United States Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 15. Canada Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 17. Canada Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 18. Canada Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 19. Mexico Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 21. Mexico Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 22. Mexico Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 23. Europe Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 25. Europe Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 26. Europe Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 27. Europe Contraceptive Drugs Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 30. Germany Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 31. Germany Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 32. France Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 34. France Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 35. France Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 36. Italy Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 38. Italy Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 39. Italy Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 40. United Kingdom Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 42. United Kingdom Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 43. United Kingdom Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 44. Russia Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 46. Russia Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 47. Russia Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 48. Netherlands Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 50. Netherlands Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 51. Netherlands Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 52. Spain Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 54. Spain Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 55. Spain Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 56. Turkey Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 58. Turkey Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 59. Turkey Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 60. Poland Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 62. Poland Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 63. Poland Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 64. South America Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 66. South America Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 67. South America Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 68. South America Contraceptive Drugs Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 71. Brazil Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 72. Brazil Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 73. Argentina Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 75. Argentina Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 76. Argentina Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 77. Asia-Pacific Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 79. Asia-Pacific Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 80. Asia-Pacific Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 81. Asia-Pacific Contraceptive Drugs Market Share (%), By Country, 2017-2031F
• Figure 82. India Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 84. India Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 85. India Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 86. China Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 88. China Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 89. China Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 90. Japan Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 92. Japan Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 93. Japan Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 94. Australia Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 96. Australia Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 97. Australia Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 98. Vietnam Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 100. Vietnam Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 101. Vietnam Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 102. South Korea Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 104. South Korea Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 105. South Korea Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 106. Indonesia Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 108. Indonesia Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 109. Indonesia Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 110. Philippines Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 112. Philippines Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 113. Philippines Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 114. Middle East & Africa Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 116. Middle East & Africa Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 117. Middle East & Africa Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 118. Middle East & Africa Contraceptive Drugs Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 121. Saudi Arabia Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 122. Saudi Arabia Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 123. UAE Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 125. UAE Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 126. UAE Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 127. South Africa Contraceptive Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Contraceptive Drugs Market Share (%), By Drug Class, 2017-2031F
• Figure 129. South Africa Contraceptive Drugs Market Share (%), By Gender, 2017-2031F
• Figure 130. South Africa Contraceptive Drugs Market Share (%), By Distribution, 2017-2031F
• Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global contraceptive drugs market is projected to witness a CAGR of 7.77% during the forecast period 2024-2031, growing from USD 19.19 billion in 2023 to USD 34.92 billion in 2031. The market demand for contraceptive pharmaceutical products is anticipated to thrive in the forecast period due to increased awareness of family planning, rising demand for women's health products, and various technological advancements contributing to the market's growth.

Contraceptive drug is a method to prevent unwanted pregnancies, increase birth control rate, and reduce the risk of sexually transmitted diseases (STDs). It mainly includes hormonal contraceptives such as oral contraceptives, injectors such as pills, and implants that release hormones over time. These drugs work by regulating hormones to suppress ovulation, change the uterus lining, or thicken cervical mucus, thereby reducing the chance of fertilization. In addition to their primary function of preventing pregnancy, birth control pills can also provide benefits such as regulating menstrual cycles, reducing menstrual pain, and reducing the risk of certain reproductive health problems. The growing demand for effective family planning options, coupled with advances in formulation and delivery methods, is driving innovation in the contraceptive drug market, making it a critical aspect of reproductive health care. For instance, in July 2023, the 'Maternal Health Initiative' report published by the Wilson Center estimated that approximately 240 babies are born every minute in lower income countries compared to 25 per minute in those with higher incomes. This report further suggested that decline in the total birth rate is driven by several factors, including increased access to contraception and reproductive health care, an increase in the number of women seeking higher education, the strengthening of women's influence in the labor force, and a decrease in the number of children worldwide.

Increasing Awareness about Reproductive Health to Fuel the Adoption of Contraceptive Drugs

Increased awareness of reproductive health has become a major driver of the contraceptive drugs market, creating a more informed society that prioritizes family planning and sexual health. Educational campaigns by health organizations, governments, and NGOs have been instrumental in spreading knowledge about reproductive rights and available contraceptive options. Social media platforms further amplify these efforts, facilitating open discussions and destigmatizing conversations surrounding contraception. As individuals become more educated about their reproductive choices, they are more likely to seek out and utilize contraceptive methods, leading to an increased demand for effective and accessible contraceptive drugs. This shift not only empowers individuals to make informed decisions about their bodies but also helps improve public health outcomes by reducing unintended pregnancies and sexually transmitted infections. For instance, in July 2023, the U.S. Food Drug and Administration (FDA) approved Opill, the first nonprescribed daily contraceptive tablet. the approval is expected to significantly improve access to contraceptives and promote better reproductive health outcomes. Opill contraceptive contains a single hormone - progestin, also known as progesterone (or nororgestrel) to prevent pregnancy. It inhibits ovulation, thickens cervical mucus to prevent sperm from reaching the egg, and alters the uterine lining to prevent implantation of fertilized egg.

Increasing Technological Advancement in Drug Development

Increasing Technological Advancement in Drug Development for delivering medicine, such as injectable contraceptives, patches, and extended-release pills, which are much more convenient and likely to be adhered to. Most importantly, advances in personalized medicine enabled the tailoring of specific birth control options to a person's preferences and health situation, taking into account needs such as side effect control and balancing hormones. They have also improved the safety and efficiency of these commodities through better production procedures and quality control systems. Additionally, reproductive health tracking and access to contraception can be integrated through digital health technology, such as telemedicine services and smartphone applications. The development of these technologies not only improved the user experience but also opened the market to a significantly larger audience for more reliable and innovative family planning solutions. For instance, in June 2023, Agile Therapeutics, Inc. (Agile), partnered with VitaCare Prescription Services, Inc. (VitaCare), a wholly owned subsidiary of GoodRx Holdings, Inc. VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications. Through this partnership, Agile is utilizing the VitaCare platform to expand patient access to the Twirla transdermal system.

Oral Contraceptive Pills Segment to Dominate the Contraceptive Drugs Market

The oral contraceptive pills (OCPs) segment will lead the way in contraceptive drugs due to a high degree of acceptance, along with their effectiveness and convenience. Available in various formulations, from combination pills to progestin-only options, the appeal is broad in meeting diverse individual needs and preferences. The direct link between increased adoption rates of OCPs and increased gains in awareness of reproductive rights and health education arises because OCPs prevent pregnancy while improving health conditions, regulating menstrual cycles, and reducing symptoms of conditions such as polycystic ovary syndrome. For instance, in November 2023, the European Parliamentary Forum for Sexual and Reproductive Rights (EPF), Family Planning 2030 (FP2030), and the International Planned Parenthood Federation (IPPF) East & Southeast Asia and Oceania Region collaborated to launch the Contraception Policy Atlas Asia and the Pacific. According to data from the United Nations Population Fund (UNFPA), 140 million women of reproductive age in Asia and the Pacific have an unmet need for modern methods of family planning. Thus, the launch of this policy is expected to raise awareness about contraceptives, further driving the demand for OCPs in the region.

North America Dominates Contraceptive Drugs Market

North America is generally leading the contraceptive drugs market because of advanced healthcare infrastructure, easy access to reproductive health services, and a strong family planning culture that has been partially encouraged by sound educational campaigns on the awareness of reproductive health and increased adoption of all types of contraceptives. In addition, the availability of big pharmaceutical companies and drug innovations with continuous research into how drugs are made open up other choices of contraceptive drugs to consumers. As regulatory support and favorable policies enhance further market growth, there are contraceptive drugs that are accessible to consumers that are also affordable. For instance, in April 2023, the MeFeego Pack abortion pills manufactured by Linepharma International Limited were approved in Japan. This medication combines mifepristone and misoprostol, which have been included in WHO's essential medicines list. Thus, the drug is expected to gain a positive response and more traction in the coming years.

Future Market Scenario (2024-2031F)

The contraceptive drug market is expected to register a promising growth, facilitated by ongoing innovations, developing consumer desires, and increasing global understanding of reproductive health. As technological advances continue to convert drug development, we can expect a more efficient and personalized contraceptive implementation, including new delivery systems and formulations that improve user convenience and compliance. In addition, emphasis on women's health and reproductive rights and support of government policy can promote more opportunities to achieve birth control, especially in new markets. As societal norms continue to shift toward greater acceptance of family planning, the demand for contraceptives is expected to increase, creating a more competitive and dynamic market landscape. Overall, combining these factors sets the contraceptive market up for sustained growth and innovation in the coming years. In July 2024, FDA approved Femlyv, the first oral dissolvable hormonal contraceptive pill for people who have difficulty in swallowing their drug. The dissolvable combined oral contraceptive of norethindrone acetate and ethinyl estradiol pill. There are many variables that might cause someone to have trouble swallowing. This drug provides another treatment option and expands access to this form of contraception for people who may have experienced these problems.

Key Players Landscape and Outlook

The contraceptive drugs market is highly dynamic; market activity reported in recent years includes business agreements and regulatory approvals of products of market players. The market has witnessed various business activities like strategic mergers, acquisitions, and collaborations in recent times. The market players are actively showing interest in innovative product developments of the market to enhance the growth rate.

For instance, in July 2024, Evofem Biosciences, Inc. (Evofem), a women's contraceptive health innovator acquired global pharma Lupin Limited. Evofem approval from the Food and Drug Administration (FDA) for the single-dose antimicrobial agent Solosec, which provides a complete course of therapy for two common sexual health infections, namely bacterial vaginosis and Trichomoniasis infection. Furthermore, in July 2024, Evofem has entered in a licensing with privately held Emirati healthcare company Pharma 1 Drug Store LLC, for the supply of Phexxi in the Middle East region.

In November 2023, Mithra Pharmaceuticals S.A., a company dedicated to women's health, announced that it had been granted an additional patent for NEXTSTELLIS (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States. NEXTSTELLIS is the first and only oral contraceptive that combines E4 with drospirenone, which is one of the most widely established progestins. E4 is an endogenous and tissue-selective estrogen with well-defined effects on breast tissues and liver tissues, and it occurs naturally in the human fetus during pregnancy.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Contraceptive Drugs Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug Class
    • 4.2.1.1. Oral Contraceptive Pills
      • 4.2.1.1.1. Combined Contraceptives
      • 4.2.1.1.2. Progestin-only Pills
    • 4.2.1.2. Injectable Contraceptives
    • 4.2.1.3. Topical Contraceptives
  • 4.2.2. By Gender
    • 4.2.2.1. Female
    • 4.2.2.2. Male
  • 4.2.3. By Distribution
    • 4.2.3.1. Hospital Pharmacy
    • 4.2.3.2. Retail Pharmacy
    • 4.2.3.3. Specialty Clinics
    • 4.2.3.4. Online Sales
    • 4.2.3.5. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Drug class
  • 4.3.2. By Gender
  • 4.3.3. By Distribution
  • 4.3.4. By Region

5. North America Contraceptive Drugs Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Oral Contraceptive Pills
      • 5.2.1.1.1. Combined Contraceptives
      • 5.2.1.1.2. Progestin-only Pills
    • 5.2.1.2. Injectable Contraceptives
    • 5.2.1.3. Topical Contraceptives
  • 5.2.2. By Gender
    • 5.2.2.1. Female
    • 5.2.2.2. Male
  • 5.2.3. By Distribution
    • 5.2.3.1. Hospital Pharmacy
    • 5.2.3.2. Retail Pharmacy
    • 5.2.3.3. Specialty Clinics
    • 5.2.3.4. Online Sales
    • 5.2.3.5. Others
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Contraceptive Drugs Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drug Class
        • 5.3.1.2.1.1. Oral Contraceptive Pills
        • 5.3.1.2.1.1.1. Combined Contraceptives
        • 5.3.1.2.1.1.2. Progestin-only Pills
        • 5.3.1.2.1.2. Injectable Contraceptives
        • 5.3.1.2.1.3. Topical Contraceptives
      • 5.3.1.2.2. By Gender
        • 5.3.1.2.2.1. Female
        • 5.3.1.2.2.2. Male
      • 5.3.1.2.3. By Distribution
        • 5.3.1.2.3.1. Hospitals Pharmacy
        • 5.3.1.2.3.2. Retail Pharmacy
        • 5.3.1.2.3.3. Specialty Clinics
        • 5.3.1.2.3.4. Online Sales
        • 5.3.1.2.3.5. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Contraceptive Drugs Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Contraceptive Drugs Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Contraceptive Drugs Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Contraceptive Drugs Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals
• 17.3. Product Pipeline

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Pfizer Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Johnson & Johnson Services, Inc.
  • 20.3.3. Teva Pharmaceuticals Industries Ltd.
  • 20.3.4. Novartis AG
  • 20.3.5. Piramal Enterprises Ltd
  • 20.3.6. AbbVie Inc.
  • 20.3.7. Veru Inc.
  • 20.3.8. Maxwellia Ltd.
  • 20.3.9. Perrigo Company plc.
  • 20.3.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer